Boston Scientific (NYSE: BSX) today announced the completion of its $3.7 billion acquisition of Axonics, Inc. (Nasdaq: AXNX).

Boston Scientific announced the acquisition in January, but the review timeline dragged on after the Federal Trade Commission ...

Boston Scientific, a Marlborough medical device manufacturer, has officially closed its acquisition of Axonics Inc. after entering into a purchase agreement in January.

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy.

Axonics (NASDAQ:AXNX) quickly edged higher by 0.8% after a Nasdaq delisting notice for its planned sale to Boston Scientific ...

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to ...

Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...

Boston Scientific Corporation (NYSE:BSX)宣布恢复其AVANT GUARD临床试验,该试验针对一组新的持续性心房颤动未经药物治疗的患者。此前该试验因需要评估观察结果而暂停,但经过仔细审查并与研究数据监测委员会协商后,试验招募将继续进行。 AVANT GUARD试验是Boston Scientific的一项重要研究,该公司以开发和生产用于介入医学专科的医疗器械而 ...

Robust revenue growth and solid market positioning underscore Boston Scientific's strengths. Operational challenges and competitive pressures highlight potential areas for improvement. Emerging ...

Boston Scientific (BSX) announced it has entered into a definitive agreement to acquire Cortex, Inc., an Ajax Health company. Cortex is a ...